{
  "url": "https://struct.news/briefs/immunome-has-more-cash-zero-revenue-and-a-bigger-research-bill",
  "title": "Immunome has more cash, zero revenue, and a bigger research bill",
  "summary": "Cash rose 51% to $217.7M even as six-month operating cash outflow widened to $120.3M.",
  "published_at": "2026-08-11T23:47:20.184246+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Immunome, Inc.",
    "ticker": "IMNM",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-11",
    "accession": "0001193125-26-344636",
    "url": "https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-06",
    "url": "https://www.sec.gov/Archives/edgar/data/1472012/000095017025104035/imnm-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 6941000,
      "display": "$6.9M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344636",
        "filing_date": "2026-08-11"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": -23.227519079747815,
      "display": "-23.2%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344636",
        "filing_date": "2026-08-11"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -3228.828699034721,
      "display": "-3228.8%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-344636",
        "filing_date": "2026-08-11"
      }
    }
  ],
  "watch_next": [
    {
      "type": "regulation",
      "statement": "Regulatory approval timing and foreign price controls remain explicit constraints on commercialization and potential revenue.",
      "importance": "medium",
      "evidence": "In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.",
      "source_date": "2026-08-11"
    }
  ],
  "related_tickers": [
    "IMNM"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}